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Chronic hemodialysis (HD) patients increase erythrocyte
susceptibility to hemolysis and impair cell survival. We
explored whether electrolyte-reduced water (ERW) could
palliate HD-evoked erythrocyte impairment and anemia.
Forty-three patients undergoing chronic HD were enrolled
and received ERW administration for 6 month. We evaluated
oxidative stress in blood and plasma, erythrocyte
methemoglobin (metHb)/ferricyanide reductase activity,
plasma metHb, and proinflammatory cytokines in the chronic
HD patients without treatment (n¼ 15) or with vitamin C
(VC)- (n¼ 15), vitamin E (VE)-coated dialyzer (n¼ 15), or ERW
treatment (n¼ 15) during an HD course. The patients showed
marked increases (15-fold) in blood reactive oxygen species,
mostly H2O2, after HD without any treatment. HD resulted in
decreased plasma VC, total antioxidant status, and
erythrocyte metHb/ferricyanide reductase activity and
increased erythrocyte levels of phosphatidylcholine
hydroperoxide (PCOOH) and plasma metHb. Antioxidants
treatment significantly palliated single HD course-induced
oxidative stress, plasma and RBC PCOOH, and plasma metHb
levels, and preserved erythrocyte metHb /ferricyanide
reductase activity in an order VC4ERW4VE-coated dialyzer.
However, ERW had no side effects of oxalate accumulation
easily induced by VC. Six-month ERW treatment increased
hematocrit and attenuated proinflammatory cytokines profile
in the HD patients. In conclusion, ERW treatment
administration is effective in palliating HD-evoked oxidative
stress, as indicated by lipid peroxidation, hemolysis, and
overexpression of proinflammatory cytokines in HD patients.
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In patients undergoing hemodialysis (HD), the interaction of
blood with non-biological materials of the extracorporeal
circuit can activate polymorphonuclear leukocytes to pro-
duce quantities of reactive oxygen species (ROS), which
impair neighboring tissues/cells (including RBCs) and evoke
an inflammatory response.1–4 The plasma levels of pro-
inflammatory cytokines (e.g., interleukin (IL)-1, IL-6, tumor
necrosis factor-a, and C-reactive protein) are significantly
elevated in uremic patients on dialysis,3,5 and the expression
can be augmented further even after a single HD session.3,6
Increased oxidative stress and proinflammatory cytokines
in HD patients are related to malnutrition,7 resistance to
erythropoietin therapy,8 cardiovascular events,9,10 and high
mortality.11
There is increasing evidence that oxidative stress plays a
key role in the genesis and severity of dialysis anemia.12–14 It
reduces RBC survival,15 impairs the effect of erythro-
poietin,16,17 and increases the susceptibility to hemolysis
owing to inflammatory, infectious, and mechanical stimu-
li.13,18 During the process of oxidative stress, RBCs are subject
to membrane lipid peroxidation and susceptible to destruc-
tion.19–21 Increased ROS can oxidize oxyhemoglobin to yield
H2O2 and methemoglobin (metHb)
22,23 that, in turn, leads to
tissue hypoxia,24 endothelial cell G2/M arrest, and apopto-
sis.25 Increased H2O2 repressed metHb reductase expression
in HeLa cells;26 deficiency of the enzyme, an autosomal
recessive trait, results in hereditary methemoglobinemia
(hemolysis).27 A trans-plasma membrane electron transport
system (e.g., nicotinamide adenine dinucleotide (reduced
form)-ferricyanide reductase and NADH-metHb reductase)
is present on RBC membranes and plays a role to reduce
cytotoxic ferricyanide/metHb to functional ferrocyanide/
oxyhemoglobin.28,29 Intravenous vitamin C (VC)- or vitamin
E (VE)-coated dialyzer can improve HD-enhanced erythro-
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cyte lipid peroxidation and hemolysis via the preserva-
tion of NADH-ferricyanide reductase and NADH-metHb
reductase.4
Electrolyte-reduced water (ERW) obtained by electrolysis
scavenges O2
K, H2O2, and HOCl,
3,30 and protects DNA from
oxidative damage.30 The protective mechanism of ERW
results from active atomic hydrogen with high reducing
ability, which can contribute to ROS-scavenging activity, and
may participate in the redox regulation of cellular function.30
Active hydrogen in ERW may be an ideal scavenger against
ROS because it does not produce oxidized molecules after
reduction like other organic antioxidants (VC, VE, and
polyphenols).31 Our previous data reported that ERW
administration diminished HD-enhanced H2O2 and HOCl
activity, minimized atherosclerotic, oxidized and inflamma-
tory markers, and partly restored total antioxidant status
(TAS) during 1-month treatment.3 In this study, 6 monthd of
HD session was used in this study as in vivo system to
evaluate the effects of ERW on dialysis-induced oxidative
stress as indicated by erythrocyte lipid peroxidation,
erythrocyte reductase activity, and metHb (hemolysis) levels.
We also examined the long-term outcome of ERW on
hematocrit, erythropoietin dose, and proinflammatory cyto-
kine profiles in patients with end-stage renal disease (ESRD).
RESULTS
ERW-reduced HD-enhanced ROS formation in the blood
An average 15-fold increase in blood ROS activity was noted
in patients who underwent HD without ERW treatment.
Replacement of ERW could effectively suppress the ROS
formation by 75714% in HD patients (Figure 1a). VC- or
VE-coated dialyzer inhibited HD-enhanced ROS by 83711
or 4979%.
Post-HD blood samples obtained from the group were
used for examining the effects of several antioxidants. The
augmented blood ROS counts were greatly inhibited by an
H2O2 scavenger, catalase (by 6878%), and partially
depressed by superoxide dismutase (1475%) and epigallo-
catechin-3-gallate (1675%) (Figure 1b), indicating that the
majority of the blood ROS activity was derived from H2O2.
ERW depressed ROS activity by 6078%.
ERW preserved HD-reduced plasma TAS
In the XERW group, the post-HD plasma VC and TAS levels
were significantly decreased (Figure 2). This indicates that
HD can cause acute oxidative stress and acute loss of plasma
VC. In the VC group, intravenous VC significantly (Po0.05)
increased the plasma VC and TAS levels in ESRD patients
receiving HD. Patients for whom the VE-coated dialyzer was
used did not seem to have restored plasma VC and TAS levels.
ERW treatment could restore plasma VC and TAS levels.
In all four groups, there was no significant change in plasma
VE and oxalate concentrations. However, an increased
tendency of oxalate concentration was found in the VC
group, suggesting a possibly adverse side effect of long-term
intravenous VC.
ERW decreased HD-enhanced ROS and PCOOH in the plasma
and RBC membrane
In our previous studies,3,4 a single session of HD did not
affect the levels of lipid profiles in the ESRD patients. The
baseline level of pre-HD plasma phosphatidylcholine hydro-
peroxide (PCOOH) and erythrocyte membrane PCOOH was
similar among the four groups of patients. However, in the
XERW group, the post-HD plasma PCOOH (205724 pmol/
ml) and post-HD erythrocyte membrane PCOOH levels
(310739 pmol/ml) were significantly (Po0.05) increased
after HD (Figure 3). Intravenous VC significantly (Po0.05)
prevented increases in post-HD plasma PCOOH (1107
15 pmol/ml) and in post-HD RBC membrane PCOOH levels
(168725 pmol/ml). In the VE group, the VE-coated dialyzer
also decreased the increase in post-HD plasma PCOOH level
(145721 pmol/ml, Po0.05). On the other hand, the VE-
coated dialyzer also prevented the increase in post-HD RBC
membrane PCOOH levels (178729 pmol/ml, Po0.05). In
the ERW group, ERW treatment significantly reduced post-
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Figure 1 | (a) On palliating ROS formation in HD-activated blood,
the effects of intravenous VC, a VE-coated dialyzer, and ERW are
clarified. (b) The effects of superoxide dismutase, catalase (CAT),
epigallocatechin-3-gallate (EGCG), VC, VE, or ERW on post-HD-
enhanced blood ROS activity in vitro are displayed for comparison. VC
group (n¼ 15), HD patients with intravenous VC; VE group (n¼ 15),
HD patients with VE-coated dialyzer; ERW group (n¼ 15), HD patients
with ERW treatment; and XERW group (n¼ 15), HD patients without
VC, VE-coated dialyzer, or ERW treatment. Pre-HD¼before an HD
session; post-HD¼ after the HD session (corrected for hemoconcen-
tration). *Po0.05 vs pre-HD value; #Po0.05 vs XERW group.
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HD plasma PCOOH (134718 pmol/ml, Po0.05) and post-
HD RBC membrane PCOOH levels (163719 pmol/ml,
Po0.05).
ERW reduced HD-triggered metHb formation
A single session of HD inhibited the activities of NADH-
metHb reductase and NADH-ferricyanide reductase in
erythrocytes, and it increased plasma metHb levels (Figure 4).
Intravenous VC, VE, or ERW treatment significantly
preserved the activities of erythrocyte ferricyanide reductase
and erythrocyte metHb reductase, and decreased the HD-
augmented metHb level. These findings imply that ERW
treatment was effective in preventing oxidative stress on
erythrocytes.
Long-term effect of ERW on HD-induced oxidative stress and
inflammatory markers
To determine the long-term effects of ERW in the ESRD
patients undergoing chronic HD, we recorded the post-HD
blood ROS, post-HD levels of activities of NADH-metHb
reductase and NADH-ferricyanide reductase in erythrocyte
membrane, and post-HD plasma metHb level in the ERW-
and XERW-treated patients for 6 months. As shown in
Figure 5, after 6 months of ERW treatment in the ESRD
patients with chronic HD, the increased post-HD blood ROS
was decreased (Po0.05) when compared to XERW group,
whereas the post-HD levels of activities of NADH-metHb
reductase and NADH-ferricyanide reductase were increased
(Po0.05) when compared to the XERW group. The post-HD
plasma metHb level was also significantly decreased
(Po0.05) in the ERW group when compared to the XERW
group. The long-term outcome showed that 6-month ERW
treatment significantly increased hematocrit (from 28.970.7
to 31.570.6%) at a similar dose of erythropoietin admin-
istration in the 43 chronic HD patients (Figure 6). However,
the differences of hematocrit change were not statistically
significant in the XERW group (from 31.071.0 to 30.77
0.4%) even at a similar dose of erythropoietin. Furthermore,
after 6 months of ERW treatment, 26 plasma cytokines
critical to the inflammatory response are also downregulated
(Figure 7).
DISCUSSION
Our study indicates that HD activated polymorphonuclear
leukocytes and monocytes to release of ROS, mostly H2O2
3,4
and was accompanied by adverse events in ESRD patients,
including (1) increased amount of ROS in the blood;
(2) peroxidation of plasma lipid and RBC membrane lipid;
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Figure 2 | Effects of intravenous infusion of VC, VE-coated
dialyzer VE, or ERW on plasma VC, VE, TAS, and plasma oxalate
(Oxalate) levels during a hemodialysis session. VC group (n¼ 15),
HD patients with intravenous VC; VE group (n¼ 15), HD patients with
VE-coated dialyzer; ERW group (n¼ 15), HD patients with ERW
dialysate; and XERW group (n¼ 15), HD patients without VC,
VE-coated dialyzer, or ERW dialysate. Pre-HD¼before an HD session;
post-HD¼ after the HD session (corrected for hemoconcentration).
*Po0.05 vs pre-HD value; #Po0.05 vs XERW group.
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Figure 3 | Mean values of pre/post-HD blood H2O2–luminol
counts, and PCOOH level in plasma and in RBC membrane are
displayed. VC group (n¼ 15), HD patients with intravenous VC; VE
group (n¼ 15), HD patients with VE-coated dialyzer; ERW group
(n¼ 15), HD patients with ERW dialysate; and XERW group (n¼ 15),
HD patients without VC, VE-coated dialyzer, or ERW treatment.
Pre-HD¼before an HD session; post-HD¼ after the HD session
(corrected for hemoconcentration). *Po0.05 vs pre-HD value;
#Po0.05 vs XERW group.
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(3) inhibition of the activity of erythrocyte reductases,
leading to hemolysis. The application of ERW can decrease
HD-enhanced blood ROS production, RBC lipid peroxida-
tion, and hemolysis via the preservation of NADH-ferricya-
nide reductase and -metHb reductase activity. This beneficial
long-term outcome of 6-month ERW treatment can improve
the hematocrit without the increment of erythropoietin
dosage.
The oxidative stress associated with uremia is exacerbated
by hemodialysis since neutrophils and monocytes, activated
by contact with the dialysis membranes, release large
amounts of ROS.1–4 The deleterious effects of ROS on
carbohydrates, lipids, and proteins have a pathological role in
many inflammatory diseases, most of which are frequent in
HD patients.5,12 In particular, the oxidation of polyunsatu-
rated fatty acids on the RBC membrane3,4,12 increases RBC
rigidity and reduces their deformability,32,33 leading to
greater susceptibility to hemolysis,4 and shorter survival.15
ROS may cause subsequent oxidation and release of other
oxidized metabolites and are increased after HD session.3,4 As
a primary peroxidation product from membrane phospho-
lipids, the level of PCOOH in the plasma and erythrocyte
membrane was increased by HD.3,4 Further, the significant
increases of metHb and the decreased activity of two
RBC reductases (NADH-ferricyanide reductase and -metHb
reductase) in post-HD plasma and RBC implicate potential
RBC damage secondary to lipid peroxidation. Human oxy-
hemoglobin reacts with Fe(II)(CN)5H2O
3 to yield H2O2
and metHb.22 Further, metHb production can be accelerated
by H2O2.
34 In our previous study, HD-triggered H2O2
formation was positively correlated with the degree of
hemolysis and with metHb levels.4
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Figure 4 | Effects of intravenous infusion of VC, VE-coated
dialyzer, or ERW treatment on HD-affected erythrocyte
ferricyanide reductase activity, metHb reductase activity, and
plasma metHb level. VC group (n¼ 15), HD patients with
intravenous VC; VE group (n¼ 15), HD patients with VE-coated
dialyzer; ERW group (n¼ 15), HD patients with ERW dialysate
treatment; and XERW group (n¼ 15), HD patients without VC,
VE-coated dialyzer, or ERW treatment. Pre-HD¼before an HD session;
post-HD¼ after the HD session (corrected for hemoconcentration).
*Po0.05 vs pre-HD value; #Po0.05 vs XERW group.
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Figure 5 | Effects of 6-month ERW treatment on post-HD-affected
erythrocyte ferricyanide reductase activity, metHb reductase
activity, and plasma metHb level in 43 ESRD patients. Twenty-five
ESRD patients without ERW treatment (XERW) were used as control
group. M0, before ERW treatment; M1, ERW treatment for 1 month;
M2, ERW treatment for 2 months; M3, ERW treatment for 3 months;
and M6, ERW treatment for 6 months. *Po0.05 vs M0 value.
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Based upon the interesting clinical improvement of a
variety of diseases by intake of reduced water since 1985,
Hayashi35 proposed the hypothesis ‘Water Regulating Theory’.
The ideal scavenger for ROS should be active atomic
hydrogen. Active atomic hydrogen can be produced in ERW
near the cathode during electrolysis of water. ERW exhibits
high pH, low dissolved oxygen, extremely high dissolved
molecular hydrogen, and extremely negative redox potential
values.30 Shirahata et al.30 suggest that the superoxide
dismutase- and catalase-like activity of ERW is not owing to
the dissolved molecular hydrogen but owing to the active
atomic hydrogen with a higher reducing ability that may
participate in ROS-scavenging activity. Happe et al.36 indicate
that hydrogenases, which are among in the oldest enzymes
(3.8 billio years old), can reversibly split molecular hydrogen
to produce active atomic hydrogen, which participates in the
redox regulation of cellular function. The ROS-scavenging
activity of ERW is stable at 41C for over a month and was not
lost even after neutralization, repeated freezing and melting,
deflation with sonication, vigorous mixing, boiling, repeated
filtration, or closed autoclaving, but was lost by opened
autoclaving or by closed autoclaving in the presence of
tungsten trioxide which efficiently adsorbs active atomic
hydrogen.30 Active hydrogen in ERW may also be an ideal
scavenger against ROS because it does not produce oxidized
molecules after reduction like other organic antioxidants (VC,
VE, and polyphenols).3,31 ERW, VC and catechins completely
scavenged O2
K produced by the hypoxanthine-xanthine
oxidase system in sodium phosphate buffer.30 Further-
more, ERW, catalase and VC could directly scavenge
H2O2.
3,30 We found that ERW and epigallocatechin-3-gallate
can scavenge both H2O2 and HOCl, but VC only availably
removes H2O2. The scavenging ROS mechanism by ERW may
be due to the direct adsorption of ROS by active atomic
hydrogen, because no antioxidant production by TAS assay
was detected in our previous3 and the present experiment.
Furthermore, in spite of the presence of ERW, our previous
report showed a significant increase in plasma PCOOH and a
decrease in TAS from pre- to post-dialysis in the ESRD
patients, whereas the present study showed no difference in
PCOOH and TAS from pre- to post-dialysis in the ESRD
patients. This discrepancy may be due to a diet control in the
present study, because a dietary factor increased plasma
triglyceride and very low-density lipoprotein levels, which
could lead to an increase in PCOOH level and a reduction in
TAS from pre- to post-dialysis even in the presence of ERW in
our previous study.3 This result indicates that ERW with a
higher reducing ability and/or direct ROS-scavenging activity
could be used in HD patients by its stable characteristics,
cheaper expense, and strong antioxidant activity to relieve
P=0.02
P=0.001
P=0.02
H
ct
 (%
)
28
29
30
31
32
33
EP
O
 (U
nit
/kg
)
20
22
24
26
28
30
32
XERW (n=25)
ERW (n=43) 
M0 M1 M3 M6
M0 M1 M3 M6
Figure 6 | Effects of 6-month ERW treatment on post-HD-affected
hematocrit (Hct) and erythropoietin dose (EPO) in 43 ESRD
patients. Twenty-five ESRD patients without ERW treatment (XERW)
were used control group. M0, before ERW treatment; M1, ERW
treatment for 1 month; M3, ERW treatment for 3 months; and M6,
ERW treatment for 6 months.
+
a c d e f g h
i k l m n o p q
r t u v w x y z - - +s
j
bBefore ERW
After 1 M ERW
After 3 M ERW
After 6 M ERW
a b
Figure 7 | Determination of multiple cytokines determination by
cytokine antibody array in the pre-HD plasma of one ESRD
patient before and during 6-month ERW treatment. (a) The
pre-HD plasma cytokine profiles and (b) amplified dot plot of
cytokines before, after 1-month (1 M), 3-month (3 M), and 6-month
(6 M) ERW treatment are displayed. Note that ERW treatment
significantly reduced the dot-spot intensity of proinflammatory
cytokines (a–z) after 6 M of ERW treatment. a, insulin growth factor-1;
b, IL-13; c, IL-15; d, IL-16; e, IL-1b; f, IL-1ra; g, IL-2; h, IL-6; I, membrane
cofactor protein-2; j, membrane cofactor protein-3; k, membrane
cofactor protein-4; l, macrophage-colony-stimulating factor; m, MDC;
n, MIG; o, macrophage inflammatory protein-1d; p, NAP-2; q, NT-3; r,
platelet-derived growth factor-BB; s, RANTES; t, stem cell factor; u,
SDF-1; v, TARC; w, tumor growth factor-b1; x, tumor growth factor-b3;
y, tumor necrosis factor-a; z, tumor necrosis factor-b; , negative dot;
þ , positive dot.
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HD-evoked oxidative stress, preserve the activity of erythro-
cyte reductases and, and increase hematocrit during six
months of treatment. Furthermore, it is well known that VC
overdoses or long-term usage may cause secondary oxalosis
via an increase in plasma oxalate levels and the deposition of
calcium oxalate in various tissues.4,37 Therefore, the applica-
tion of ERW treatment could prevent the increased plasma
oxalate level during a single HD session or after six-month
treatment.
ESRD patients on maintenance HD show systemic
inflammation due to uremia and dialysis and suffer from
cardiovascular events7–11 and severe anemia.38 HD-augmen-
ted hemolysis has been proposed as a significant factor in
regard to HD-related shortened erythrocyte survival.28 VE
supplementation for HD patients resulted in reduced
erythropoietin dosage requirements.16 HD patients with
stable hemoglobin levels and not receiving erythropoietin
therapy exhibited a higher OH-scavenging activity when
compared with those in need of erythropoietin:39 it may be
argued that erythropoietin or anemia-associated increments
in the oxidant burden may be counterbalanced by a higher
consumption of antioxidants like VC. Tarng et al.40 reported
that the dose of erythropoietin as well as the ratio of
erythropoietin/hemoglobin was found to correlate positively
with serum concentrations of 8-hydroxy-20-deoxyguanosine,
an oxidation product of DNA. VC influenced renal synthesis
of erythropoietin in the kidneys, and production of
erythropoietin was enhanced in the presence of antioxidative
cocktail comprising vitamins A, E, and C. Also, pro-oxidants
reduced erythropoietin synthesis in human hepatoma cells.41
Our data showed that 6 months of antioxidant ERW
treatment significantly increased hematocrit but did not
increase erythropoietin dose in the 43 ESRD patients.
Antioxidants like VE and anti-inflammatory drugs can
attenuate chronic HD-evoked cardiovascular events and
neutrophil and endothelial cell apoptosis.41–44 The present
results showed that 26 proinflammatory cytokines are
downregulated after 6 months of ERW treatment. These
findings provide new insight into the molecular events that
resolve anemia and inflammation in chronic HD patients by
the ERW treatment. A further study for clarification of ERW
on immunity needs to be determined.
In conclusion, our findings demonstrate that ERW
treatment is effective in palliating HD-evoked oxidative
stress, as indicated by hemolysis and lipid peroxidation, in
HD patients. Long-term benefits of this novel therapy are
associated with an increase of hematocrit level, improvement
of erythropoietin responsiveness, and downregulation of
proinflammatory cytokines in chronic HD patients.
MATERIALS AND METHODS
Patients
To assess the extent of oxidative stress in blood of ESRD patients, 25
patients (14 men and 11 women) without any treatment (XERW
group), 15 patients (seven men and eight women) with intravenous
VC group (1 g in 250 ml of saline infused over 4 h of HD), 15
patients (eight men and seven women) with VE-coated dialyzer (VE
group), 43 patients (28 men and 15 women) subjected to ERW
treatment (ERW group) with 10.870.5 mg/dl of creatinine,
subjected to maintenance HD at Wan-Hwa Hospital for a period
of 1272 months after informed consent obtained were enrolled in
the ERW study. The criteria for patient selection included the
absence of habit of smoking, malignancy, inflammatory disorders,
chronic or acute infections, supplementation of VC or VE, and
treatment either oral or intravenous iron, or anti-inflammatory
drugs 3 months before enrollment. The mean age was 5873 years
old (mean7s.e.m., range 42–82 years). As the subjects for 6-month
study were recruited into the ERW and XERW groups, we found
that at entry the study the XERW group had a high, but not
significant, baseline hematocrit level than the ERW group (31.071.0
vs 28.970.7%, P¼ 0.097). A similar level in blood urea nitrogen
(63.572.7 vs 71.473.3 mg/dl, P¼ 0.07), creatinine (10.070.35 vs
11.070.51 mg/dl, P¼ 0.10), albumin (3.8270.05 vs 3.7870.07 g/dl,
P¼ 0.57), and ferritin (395720 vs 373738 ng/ml, P¼ 0.596) was
noted in the ERW and XERW groups. All HD patients except VE
group used hemodialyzer (AM-Bio-HX-90 and AM-Bio-HX-100
biomembrane: Asahi Kasei Med Co., Tokyo, Japan). A VE-coated
EE18 Excerbranes membrane (Terumoc Co., Japan) was used in the
VE group. The VC solution (Tai-Yu Pharmaceutical, Taipei, Taiwan)
was prepared in 1 g/250 ml of saline before use. The blood flow rate
during the dialysis sessions was 250–300 ml/min and dialysate flow
500 ml/min. The surface area of these two dialyzers was 1.5 and
1.8 m2, respectively, and patient treatment with either membrane
lasted for 6 montha. The kt/v of all these patients is maintained
between 1.3 and 1.6. The cause of ESRD was diabetes in 55 patients
and chronic glomerulonephritis in 43 patients. HD patients were on
a free diet with a normal and constant intake of essential fatty acids,
and none of them took any drug with established or potential
oxidizing effect and any antioxidants such as VC or VE during 6
months of tested period. The permission of clinical trial was
approved by the meeting of Human Research Committee of the
Wan-Hwa Regional Hospital.
ERW system
HD-24K (Nihom Trim Co., Osaka, Japan) was structured as
described in detail previously.3 In brief, raw water was supplied
after compressed by the compression pump and supplied into a
compartment for electrolysis through a solanoid valve, which opens
and closes synchronizing with the signal of water level sensor in
electrolyzed water storage tank and flow sensor. At the electric
compartment, the supplied raw water was electrolyzed by direct
current supplied to þ and  electrode plate across diaphragm and
at the side of  electrode plate reduced water containing active
hydrogen and lower redox potential value. The series of operation
are automatically carried out according to the level of reduced water
tank. HD-24K, compression pump, reduced water tank, acidic water
tank, and personal computer for control are placed in front of usual
raw water processing device. The reduced water produced by HD-
24K was collected in reduced water tank, and then was supplied to
usual raw water processing system for HD by compress with
compressing pump. The intensity of electrolysis of HD-24K is
adjusted to ‘level 2’ and the ERW that indicates pH 9.8 right after
taking from ‘out’ of HD-24K is used in this study. The quality of
ERW for HD was approved by Yen Tjing Ling Industrial Research
Institute National Taiwan University with the No. E89A299D277,
which is required by the American Association of Medical
Instruments (AAMI). The ERW dialysates maintain the properties
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of lower redox potential value when compared to that of the non-
ERW dialysate (15075 29675 mV). The microbiological quality
of the final dialysates meets the AAMI standard (obacteria of
200 colony-forming units/ml and oendotoxin concentration of
2 EU/ml). Because culture results do not become available for at
least 48 h, during which time bacteria continue to proliferate, the
final dialysate action level also meet AAMI standard (obacteria and
endotoxin of 50 colony-forming units//ml and 1 EU/ml, respec-
tively). The endotoxin level in the water used for HD is
0.06170.003 EU/ml measured by an endotoxin ELISA kit (HBT-
HIT301, Biocompare Inc., South San Francisco, CA, USA) and an
automated ELISA analyzer (CODA, SN10373, Hercules, CA, USA).
Blood samples and biochemical analysis
Blood (10 ml) was collected via the arterial line of the HD circuit,
before the start and the end of an HD session, into a heparinized
sterile test tube and was processed within 2 h. Concerning the effects
of hemoconcentration during HD, the post-HD levels of various
plasma biochemicals were corrected with the following equation:
Corrected post  HD value ¼measured post  HD value
ðCpreHD=CpostHDÞ
The whole-blood cell count, including the hemoglobin level and
hematocrit, were determined with an autoanalyzer (Coulter STKS,
Hialeah, Finland). Plasma levels of urea nitrogen and creatinine were
determined with an autoanalyzer (Hitachi 736–15, Ibaraki, Japan).
The plasma oxalate concentration was determined by an enzymatic
method.37
Measurement of ROS activity in whole blood and plasma
To determine the ROS activity in whole blood and plasma, we
sampled and isolated plasma from the four groups of patients at
various time points through the first HD session of the study. After
sampling, 0.2 ml of whole blood or plasma was immediately added
to the luminol solution, and ROS signals were measured as
described previously.4
To identify the types of ROS in the HD-activated blood, we
studied the effects of various ROS inhibitors, including superoxide
dismutase (an O2
K scavenger, 30 U), catalase (an H2O2 scavenger,
30 U), and epigallocatechin-3-gallate (an HOCl and H2O2 scavenger,
10 mg).4 To test the in vitro effects of ERW, we also compared the
ROS signals in blood samples obtained from the N group before and
after treatment with ERW.
Plasma VC and VE assay
To preserve VC, an aliquot of plasma was deproteinized with 10%
metaphosphoric acid (1:1, vol/vol), and the supernatant was kept at
801C. Plasma VC was measured by high-performance liquid
chromatography (Hitachi D-7000 HPLC system) with ultraviolet
detector at 254 nm with a Cosmosil 5 C18-MS column
(250 4.6 mm ID) with a 5-mm particle size.45
VE was measured, after extraction with ethanol and hexane, by
high-performance liquid chromatography with UV detection at
292 nm46 with a Cosmosil 5C18-MS column (150 4.6 mm ID) with
a 5-mm particle size. The system manager software (D-7000, version
3.0; Hitachi) was used for VC and VE peak integration and data
acquisition.
The extraction recoveries of standards recoveries of VC and VE
within the concentration range of the assay were 85 and 96%. For
VC and VE, within-day variability was lower than 13.5%, whereas
between-day variability did not exceed 14.8%. Within-day variability
averaged 11.472.5% for VC and 6.171.6% for VE. Mean between-
day variability was 11.972.7% for VC and 6.371.5% for VE.
Measurements of plasma TAS
We measured the TAS of plasma (20ml) by a commercial kit
(TAS kit, Randox, San Franciso, CA, USA) according to the manu-
facturer’s instructions.3,4
Measurement of lipid peroxidation products
A lipid peroxidation product, PCOOH, originating from oxidized
phosphatidylcholine is a primary lipid peroxidation product,47
which was measured to serve as an indication of oxidative stress.3,4
The amounts of PCOOH in plasma and erythrocytes were
determined in duplicate by chemiluminescence high-performance
liquid chromatography (CL-HPLC, Tohoku Electronic Ind. Co.,
Sendai, Japan).
Spectrophotometric assessment of oxidized hemoglobin and
RBC reductase activities
HD-induced oxidative stress, via erythrocyte membrane lipid
peroxidation, would lead to erythrocyte destruction and hemo-
globin release. We determined the plasma concentration of metHb
spectrophotometrically, as described previously.34 The hemolysis
score was determined by spectrophotometric measurement at
540 nm, and with a Coulter counter (Coulter Onix, Miami, FL,
USA). A reduced activity of RBC trans-plasma membrane electron
transport system, including ferricyanide reductase and metHb
reductase, could lead to cell damage and increase plasma metHb
and H2O2 concentration.
28,29 RBC ferricyanide reductase activity
was measured as described previously.48 metHb reductase activity
was assayed by use of 2,6-dichlorophenol indophenol as an electron
acceptor.49
Statistical analysis
All values are expressed as mean7s.e.m. Within-group comparisons
between pre- and post-HD values were performed by paired t-test.
For longitudinal data, repeated measures analysis of variance with
post hoc analysis with the Bonferroni procedure were used to analyze
the between- and within-group differences. Po0.05 was adopted as
indicating statistical significance.
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